Prostatype Genomics

CEO Fredrik Persson explains the significance of the recently achieved milestones on the way to the US market
Fredrik explains the significance of the three milestones achieved in the United States in February 2024, and tells us that the company expects to achieve the fourth and last, and thus reach the US market, which is valued at SEK 2 billion (USD 200 million) per year, in the near future. He also addresses the company's substantial financial potential in the United States given that Medicare approval is obtained for reimbursement, which is expected to be achieved in Q4 2024. As an example of how value-driving the US market is, Fredrik mentions that a prostate cancer testing company with operations in the United States and Medicare approval was acquired in 2021 at a valuation of approximately SEK 6 billion (USD 600 million).

Interview with the urologist and researcher Pontus Röbeck about the long-term follow-up study at the Uppsala University Hospital
Pontus talks about this unique long-term follow-up study with Prostatype® and follow-up times of 25 years, and the very promising interim data completed in December 2023. These data have been selected for presentation at the prestigious AUA conference to be held in the United States in May 2024.

To read the full newsletter, and subscribe for upcoming issues, click on this link:
https://bit.ly/progenjanfeb24en

Prostatype Genomics' newsletter is published monthly with the aim of offering broader and more in-depth information about the company's operations and progress to shareholders, investors and other stakeholders. It is produced together with the IR communications agency Honeybadger, https://www.honeybadger.se/en/

For more information, please contact:
Fredrik Persson, CEO Prostatype Genomics AB
Telephone: +46 (0)73 049 77 01
Email: fredrik.persson@prostatypegenomics.com

Om Prostatype Genomics AB
Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.